ProText Mobility, Inc. (TXTM)
USD 0.0
(-11.11%)
USD 0.0
(-11.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -52.64 Thousand USD | 12.46% |
| 2022 | -60.13 Thousand USD | 30.08% |
| 2021 | -86 Thousand USD | -4.88% |
| 2020 | -82 Thousand USD | 0.0% |
| 2019 | - USD | 100.0% |
| 2018 | -321.5 Thousand USD | 35.64% |
| 2017 | -499.57 Thousand USD | -72.03% |
| 2016 | -290.4 Thousand USD | 0.0% |
| 2013 | -927.3 Thousand USD | 38.91% |
| 2012 | -1.51 Million USD | 45.94% |
| 2011 | -2.8 Million USD | 37.58% |
| 2010 | -4.49 Million USD | -14.63% |
| 2009 | -3.92 Million USD | -4.19% |
| 2008 | -3.76 Million USD | -3.33% |
| 2007 | -3.64 Million USD | -12.8% |
| 2006 | -3.23 Million USD | 9.61% |
| 2005 | -3.57 Million USD | -203.92% |
| 2004 | -1.17 Million USD | -36.34% |
| 2003 | -862.7 Thousand USD | -95.75% |
| 2002 | -440.72 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4530.00 USD | 76.66% |
| 2024 Q1 | -19.41 Thousand USD | -266.23% |
| 2023 Q3 | -6420.00 USD | 75.02% |
| 2023 Q4 | -5300.00 USD | 17.45% |
| 2023 FY | -52.64 Thousand USD | 12.46% |
| 2023 Q1 | -15.22 Thousand USD | -121.22% |
| 2023 Q2 | -25.7 Thousand USD | -68.86% |
| 2022 Q2 | -25 Thousand USD | -13.64% |
| 2022 FY | -60.13 Thousand USD | 30.08% |
| 2022 Q1 | -22 Thousand USD | 0.0% |
| 2022 Q3 | -6740.00 USD | 73.04% |
| 2022 Q4 | -6880.00 USD | -2.08% |
| 2021 Q3 | -24 Thousand USD | -20.0% |
| 2021 Q1 | -20 Thousand USD | 0.0% |
| 2021 FY | -86 Thousand USD | -4.88% |
| 2021 Q2 | -20 Thousand USD | 0.0% |
| 2021 Q4 | -22 Thousand USD | 8.33% |
| 2020 FY | -82 Thousand USD | 0.0% |
| 2019 FY | - USD | 100.0% |
| 2018 FY | -321.5 Thousand USD | 35.64% |
| 2017 FY | -499.57 Thousand USD | -72.03% |
| 2016 FY | -290.4 Thousand USD | 0.0% |
| 2014 Q1 | -220.39 Thousand USD | 26.41% |
| 2014 Q3 | -261.15 Thousand USD | -5.04% |
| 2014 Q2 | -248.62 Thousand USD | -12.81% |
| 2013 Q1 | -194.73 Thousand USD | 52.82% |
| 2013 FY | -927.3 Thousand USD | 38.91% |
| 2013 Q4 | -299.48 Thousand USD | -23.65% |
| 2013 Q2 | -190.88 Thousand USD | 1.98% |
| 2013 Q3 | -242.19 Thousand USD | -26.88% |
| 2012 Q1 | -393.4 Thousand USD | 53.98% |
| 2012 Q3 | -328.02 Thousand USD | 14.54% |
| 2012 FY | -1.51 Million USD | 45.94% |
| 2012 Q4 | -412.76 Thousand USD | -25.83% |
| 2012 Q2 | -383.83 Thousand USD | 2.43% |
| 2011 Q1 | -810.08 Thousand USD | 45.88% |
| 2011 Q2 | -549.49 Thousand USD | 32.17% |
| 2011 Q3 | -593.49 Thousand USD | -8.01% |
| 2011 Q4 | -854.83 Thousand USD | -44.04% |
| 2011 FY | -2.8 Million USD | 37.58% |
| 2010 Q2 | -1.17 Million USD | -23.06% |
| 2010 FY | -4.49 Million USD | -14.63% |
| 2010 Q4 | -1.49 Million USD | -70.21% |
| 2010 Q3 | -879.38 Thousand USD | 24.89% |
| 2010 Q1 | -951.43 Thousand USD | -30.04% |
| 2009 Q4 | -731.62 Thousand USD | 49.18% |
| 2009 FY | -3.92 Million USD | -4.19% |
| 2009 Q1 | -1.01 Million USD | 68.18% |
| 2009 Q2 | -741.62 Thousand USD | 26.66% |
| 2009 Q3 | -1.43 Million USD | -94.13% |
| 2008 FY | -3.76 Million USD | -3.33% |
| 2008 Q4 | -3.17 Million USD | -34.1% |
| 2008 Q3 | -2.36 Million USD | -126.12% |
| 2008 Q2 | -1.04 Million USD | -45.38% |
| 2008 Q1 | -720.8 Thousand USD | 20.93% |
| 2007 Q4 | -911.55 Thousand USD | -14.31% |
| 2007 FY | -3.64 Million USD | -12.8% |
| 2007 Q2 | -1.14 Million USD | -45.34% |
| 2007 Q1 | -789.11 Thousand USD | 5.28% |
| 2007 Q3 | -797.46 Thousand USD | 30.47% |
| 2006 Q3 | -709.87 Thousand USD | 14.1% |
| 2006 FY | -3.23 Million USD | 9.61% |
| 2006 Q2 | -826.42 Thousand USD | -11.74% |
| 2006 Q1 | -739.61 Thousand USD | 70.23% |
| 2006 Q4 | -833.1 Thousand USD | -17.36% |
| 2005 Q2 | -346.72 Thousand USD | -20.84% |
| 2005 FY | -3.57 Million USD | -203.92% |
| 2005 Q1 | -286.93 Thousand USD | -4.36% |
| 2005 Q3 | -456.81 Thousand USD | -31.75% |
| 2005 Q4 | -2.48 Million USD | -443.8% |
| 2004 FY | -1.17 Million USD | -36.34% |
| 2004 Q2 | -315.59 Thousand USD | -1.64% |
| 2004 Q3 | -275.13 Thousand USD | 12.82% |
| 2004 Q1 | -310.5 Thousand USD | 35.23% |
| 2004 Q4 | -274.96 Thousand USD | 0.07% |
| 2003 Q1 | -141.5 Thousand USD | 0.0% |
| 2003 FY | -862.7 Thousand USD | -95.75% |
| 2003 Q4 | -479.35 Thousand USD | -388.29% |
| 2003 Q3 | -98.17 Thousand USD | 31.67% |
| 2003 Q2 | -143.66 Thousand USD | -1.53% |
| 2002 FY | -440.72 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 96.058% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 98.956% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 99.705% |
| Nascent Biotech, Inc. | -2.22 Million USD | 97.639% |
| Rebus Holdings, Inc. | -664 Thousand USD | 92.072% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.064% |
| Qrons Inc. | -643.67 Thousand USD | 91.822% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 86.488% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.905% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 87.33% |
| Skye Bioscience, Inc. | -13.67 Million USD | 99.615% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.927% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 101.071% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 79.887% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.931% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 98.153% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 96.573% |
| Mesoblast Limited | -84.14 Million USD | 99.937% |
| Marizyme, Inc. | -34.08 Million USD | 99.846% |
| Genus plc | 6.4 Million USD | 100.823% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.54% |
| Pharming Group N.V. | -4.87 Million USD | 98.921% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 97.35% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 94.348% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 99.37% |
| ContraFect Corporation | -56.88 Million USD | 99.907% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 98.844% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 96.245% |
| IMV Inc. | -38.67 Million USD | 99.864% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 98.086% |
| MultiCell Technologies, Inc. | -722.81 USD | -7182.688% |
| ONE Bio Corp. | 13.68 Million USD | 100.385% |
| Accustem Sciences Inc. | -3.74 Million USD | 98.595% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.911% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 89.103% |
| Q BioMed Inc. | -3.44 Million USD | 98.472% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 101.487% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 97.997% |
| Biomind Labs Inc. | -1 Million USD | 94.786% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.904% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 98.186% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 99.208% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 97.177% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -75.748% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.668% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 97.276% |
| GB Sciences, Inc. | -1.42 Million USD | 96.294% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.458% |
| HST Global, Inc. | -140.9 Thousand USD | 62.642% |
| CSL Limited | 3.7 Billion USD | 100.001% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 95.32% |
| Halberd Corporation | -75.05 Thousand USD | 29.86% |
| Enzolytics Inc. | -2.14 Million USD | 97.55% |
| Agentix Corp. | -1.37 Million USD | 96.163% |
| Resverlogix Corp. | -12.74 Million USD | 99.587% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 98.339% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.988% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 94.958% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 98.197% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 96.667% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 98.454% |
| AVAX Technologies, Inc. | 6.69 Million USD | 100.787% |
| Zenith Capital Corp. | -8.94 Million USD | 99.411% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.987% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -202.164% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 97.856% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 69.308% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 97.374% |
| Kadimastem Ltd | -3.04 Million USD | 98.269% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 94.651% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 95.809% |
| BioStem Technologies, Inc. | -7.77 Million USD | 99.323% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 70.995% |
| LadRx Corporation | -3.82 Million USD | 98.623% |
| Cell Source, Inc. | -4.32 Million USD | 98.783% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 92.337% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 92.337% |
| NovAccess Global Inc. | -2.46 Million USD | 97.866% |
| Affymax, Inc. | -15.04 Million USD | 99.65% |
| Itoco Inc. | -919.14 Thousand USD | 94.273% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 98.758% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 95.296% |
| Mobile Lads Corp. | -554.55 Thousand USD | 90.508% |
| CytoDyn Inc. | -18.05 Million USD | 99.708% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -109.138% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 76.081% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 90.679% |
| SYBLEU INC | -149.18 Thousand USD | 64.714% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 97.102% |
| International Stem Cell Corporation | -663 Thousand USD | 92.06% |
| Bioxytran, Inc. | -3.82 Million USD | 98.622% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -158.8% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.855% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 96.747% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 92.846% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 98.308% |
| Neutra Corp. | -229.48 Thousand USD | 77.062% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 99.7% |
| PureTech Health plc | -146.19 Million USD | 99.964% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 99.755% |
| IXICO plc | -1.43 Million USD | 96.337% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 99.445% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.957% |
| CSL Limited | 3.81 Billion USD | 100.001% |
| Cellectis S.A. | -108.85 Million USD | 99.952% |